Cytek Biosciences Inc. (CTKB)
NASDAQ: CTKB
· Real-Time Price · USD
3.38
-0.01 (-0.29%)
At close: Sep 26, 2025, 1:14 PM
Cytek Biosciences Revenue Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product Revenue | 31.41M | 28.11M | 79.6M | 39.54M | 34.58M | 34.12M | 46.65M | 38.44M | 40.45M | 31.17M | 43.64M | 36.39M | 37.09M | 31.48M | 35.95M | 32.19M | 28.92M |
| Product Revenue Growth | +11.76% | -64.68% | +101.29% | +14.37% | +1.33% | -26.86% | +21.36% | -4.97% | +29.77% | -28.57% | +19.92% | -1.90% | +17.83% | -12.44% | +11.68% | +11.30% | n/a |
| Service Revenue | 44.02M | 42.44M | n/a | 39M | 36.95M | 36.87M | n/a | 37M | 9.24M | 5.92M | 4.7M | 4.09M | 3.07M | 3.58M | 2.94M | 2.19M | 12.47M |
| Service Revenue Growth | +3.73% | n/a | -100.00% | +5.54% | +0.23% | n/a | -100.00% | +300.38% | +56.20% | +25.90% | +14.95% | +33.33% | -14.43% | +21.79% | +34.65% | -82.48% | n/a |
Revenue by Geography
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asia Pacific Revenue | 7.87M | 8.89M | 20.48M | 8.94M | 8.98M | 6.35M | 11.57M | 6.76M | 7.05M | 6.22M | 4.22M | 7.15M | 6.14M | 5.01M | 6.63M | 2.8M | 3.39M |
| Asia Pacific Revenue Growth | -11.52% | -56.59% | +129.18% | -0.52% | +41.46% | -45.09% | +71.17% | -4.20% | +13.36% | +47.55% | -41.05% | +16.46% | +22.57% | -24.43% | +136.74% | -17.37% | n/a |
| Emea Revenue | 12.31M | 11.57M | 29.98M | 17.23M | 13.77M | 15.13M | 21.14M | 12.92M | 9.08M | 10.03M | 16.14M | 10.3M | 8.84M | 8.68M | 13.48M | 6.18M | 111K |
| Emea Revenue Growth | +6.42% | -61.43% | +74.01% | +25.11% | -8.94% | -28.45% | +63.60% | +42.25% | -9.44% | -37.83% | +56.64% | +16.55% | +1.77% | -35.60% | +118.24% | +5466.67% | n/a |
| Other Revenue | 1.53M | 2.46M | 6.73M | 979K | 1.47M | 2.02M | 1.51M | 1.53M | 2.12M | 996K | 1.29M | 212K | 418K | 1.04M | 633K | 1.42M | 17.25M |
| Other Revenue Growth | -37.85% | -63.36% | +587.23% | -33.27% | -27.56% | +34.11% | -1.44% | -27.60% | +112.45% | -22.67% | +507.55% | -49.28% | -59.96% | +64.93% | -55.30% | -91.79% | n/a |
| United States Revenue | 23.89M | 18.54M | 46.9M | 24.35M | 22.39M | 21.36M | 24.02M | 26.79M | 31.44M | 19.84M | 26.7M | 22.81M | 24.76M | 20.32M | 18.14M | 23.98M | n/a |
| United States Revenue Growth | +28.91% | -60.48% | +92.58% | +8.75% | +4.85% | -11.07% | -10.35% | -14.79% | +58.48% | -25.69% | +17.03% | -7.88% | +21.83% | +12.01% | -24.33% | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 25.66M | 25.41M | 20.94M | 23.37M | 23.96M | 23.95M | 22.32M | 22.43M | 25.15M | 23.23M | 19.54M | 16.85M | 17.02M | 14.51M | 15.23M | 12.24M | 9.74M | 8.26M | 7.19M | 5.53M | 5.57M | 6.07M |
| Selling, General, and Administrative Revenue Growth | +1.02% | +21.31% | -10.39% | -2.47% | +0.05% | +7.33% | -0.49% | -10.84% | +8.30% | +18.85% | +15.97% | -0.96% | +17.28% | -4.75% | +24.49% | +25.63% | +17.92% | +14.91% | +30.01% | -0.77% | -8.19% | n/a |
| Research and Development Revenue | 8.83M | 9.72M | 9.72M | 9.88M | 10M | 9.8M | 10.87M | 11.17M | 12.14M | 9.97M | 9.75M | 8.65M | 8.44M | 8.03M | 7.08M | 6.08M | 6.19M | 5.09M | 4.38M | 3.38M | 2.92M | 3.02M |
| Research and Development Revenue Growth | -9.24% | +0.02% | -1.61% | -1.19% | +2.09% | -9.87% | -2.70% | -7.95% | +21.68% | +2.33% | +12.68% | +2.54% | +5.12% | +13.41% | +16.42% | -1.87% | +21.59% | +16.17% | +29.89% | +15.78% | -3.32% | n/a |
| Sales and Marketing Revenue | 12.13M | 12.51M | 11.87M | 12.43M | 12.27M | 12.54M | 11.56M | 12.08M | 14.37M | 11.14M | 9.03M | 8.81M | 8.43M | 6.96M | 8.3M | 6.33M | 5.58M | 4.28M | 4.56M | 3.84M | 3.06M | 3.53M |
| Sales and Marketing Revenue Growth | -3.00% | +5.35% | -4.47% | +1.31% | -2.19% | +8.49% | -4.26% | -15.95% | +28.91% | +23.44% | +2.49% | +4.50% | +21.14% | -16.18% | +31.16% | +13.54% | +30.37% | -6.21% | +18.81% | +25.47% | -13.37% | n/a |